Skip to Content
 
Stephen A.  Strickland, Jr.

Stephen A. Strickland, Jr., M.D., MSCI

Assistant Professor of Medicine (Hematology/Oncology)

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Office
    615-936-3851
  • Faxes
    Office Fax
    615-936-1812
    Clinic Fax
    615-343-7200
  • Addresses
    Clinic
    Vanderbilt University Medical Center
    1301 Medical Center Drive, 3903 The Vanderbilt Clinic
    Nashville, TN 37232-5505

    Office
    Vanderbilt University Medical Center
    1301 Medical Center Drive, 3927 The Vanderbilt Clinic
    Nashville, TN 37232-5505
Profile

Dr. Strickland is an Assistant Professor of Medicine in the Division of Hematology/Oncology. After receiving his B.S. in Zoology at Louisiana State University in Baton Rouge, he attended Barry University in Miami Shores, Florida, where he obtained an M.S.in Biomedical Sciences. Following graduate school, he attended medical school at Louisiana State University School of Medicine in New Orleans. Dr. Strickland then completed his Internal Medicine Residency and Hematology/Oncology Fellowship at Vanderbilt University Medical Center. He is a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.

Dr. Strickland's research interests revolve around translational research and early phase clincal trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Dr. Strickland is an active member of the American Society of Hematology and the American Society of Clinical Oncology.

Education
  • Louisiana State University, B.S. (Zoology), 1995
  • Barry University, M.S. (Biomedical Sciences), 1996
  • Louisiana State University School of Medicine, M.D., 2002
  • Internship/Residency - Internal Medicine, Vanderbilt University Medical Center, 2005
  • Fellowship - Hematology/Oncology, Vanderbilt University Medical Center, 2008
  • Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, 2009
Publications
  • Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol [print-electronic]. 2017 Aug; 18(8): 1061-75. PMID: 28645776, PII: S1470-2045(17)30416-3, DOI: 10.1016/S1470-2045(17)30416-3, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28645776.
  • Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS, . Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leuk. Res [print-electronic]. 2017 May 5/12/2017; 59: 55-64. PMID: 28551161, PII: S0145-2126(17)30424-1, DOI: 10.1016/j.leukres.2017.05.010, ISSN: 1873-5835.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28551161.
  • Guo Y, Strickland SA, Mohan S, Li S, Bosompem A, Vickers KC, Zhao S, Sheng Q, Kim AS. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk. Lymphoma [print-electronic]. 2017 Jan 1/13/2017; 1-15. PMID: 28084850, DOI: 10.1080/10428194.2016.1272680, ISSN: 1029-2403.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28084850.
  • Jamieson GC, Fox JA, Poi M, Strickland SA. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs. 2016 Sep; 76(13): 1245-55. PMID: 27484675, PMCID: PMC4989016, PII: 10.1007/s40265-016-0614-z, DOI: 10.1007/s40265-016-0614-z, ISSN: 1179-1950.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27484675.
  • Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, Mohan SR, Savona MR, Venters BJ, Zhou MM, Lis JT, Hiebert SW. High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Rep [print-electronic]. 2016 Aug 8/16/2016; 16(7): 2003-16. PMID: 27498870, PMCID: PMC4996374, PII: S2211-1247(16)30950-0, DOI: 10.1016/j.celrep.2016.07.032, ISSN: 2211-1247.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27498870.
  • Strickland SA, Mohan SR, Savona MR. Unfavorable-risk acute myeloid leukemia dissected. Curr. Opin. Hematol. 2016 Mar; 23(2): 144-9. PMID: 26825699, DOI: 10.1097/MOH.0000000000000225, ISSN: 1531-7048.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26825699.
  • Guo Y, Bosompem A, Mohan S, Erdogan B, Ye F, Vickers KC, Sheng Q, Zhao S, Li CI, Su PF, Jagasia M, Strickland SA, Griffiths EA, Kim AS. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics. 2015 Sep 9/24/2015; 16: 727. PMID: 26400237, PMCID: PMC4581457, PII: 10.1186/s12864-015-1929-y, DOI: 10.1186/s12864-015-1929-y, ISSN: 1471-2164.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26400237.
  • Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol [print-electronic]. 2015 Sep; 16(9): 1025-36. PMID: 26234174, PMCID: PMC4822512, PII: S1470-2045(15)00201-6, DOI: 10.1016/S1470-2045(15)00201-6, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26234174.
  • Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica [print-electronic]. 2015 Sep; 100(9): 1172-9. PMID: 26022709, PMCID: PMC4800702, PII: haematol.2015.125849, DOI: 10.3324/haematol.2015.125849, ISSN: 1592-8721.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26022709.
  • Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues [letter]. Leukemia [print-electronic]. 2014 May; 28(5): 1167-70. PMID: 24472813, PMCID: PMC4013200, PII: leu201414, DOI: 10.1038/leu.2014.14, ISSN: 1476-5551.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24472813.
  • Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Marx ER, Sinkfield KJ, Pollard HN, Plummer WD, Dupont WD, Shultz EK, Dittus RS, Stead WW, Santoro SA, Zutter MM. Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach. Am. J. Clin. Pathol. 2013 Nov; 140(5): 643-50. PMID: 24124142, PMCID: PMC4159763, PII: 140/5/643, DOI: 10.1309/AJCP8CKE9NEINQFL, ISSN: 1943-7722.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24124142.
  • Strickland SA, Raptis A, Hallquist A, Rutledge J, Chernick M, Perree M, Talbott MS, Presant CA. Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leuk. Lymphoma [print-electronic]. 2013 Mar; 54(3): 528-34. PMID: 22924433, DOI: 10.3109/10428194.2012.722217, ISSN: 1029-2403.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22924433.
  • Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant [print-electronic]. 2012 Dec; 47(12): 1535-7. PMID: 22659680, PII: bmt201288, DOI: 10.1038/bmt.2012.88, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22659680.
  • Strickland SA, Berlin JD. Hiccups: underappreciated and underrecognized. J Support Oncol. 2009 Jul; 7(4): 128-9. PMID: 19731576, ISSN: 1544-6794.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19731576.